SBK’s Class 1 Chemical Novel Drug SBK002 Approved for Clinical Trials

Chengdu Shibeikang Biomedical Technology Co., Ltd. has recently received official approval from the National Medical Products Administration (NMPA) to initiate clinical trials for its independently developed Class 1 chemical new drug, SBK002. The notice states, “In accordance with the Drug Administration Law of the People’s Republic of China and relevant regulations, following a comprehensive review, the application meets the requirements for drug registration and is hereby approved for clinical trials”.